Role of CX3C-chemokine CX3C-L/fractalkine Expression in a Model of Slowly Progressive Renal Failure
Overview
Nephrology
Authors
Affiliations
Background: The chemokine/chemokine receptor pair CX(3)C-L/CX(3)C-R is suspected to play a role in renal fibrogenesis. The aim of this study was to investigate their function in an animal model of slowly progressive chronic renal failure.
Methods: Functional data were analysed in folic acid nephropathy (FAN) at different time points (up to day 142 after induction). Immunostaining for CX(3)C-L, CD3, S100A4, collagen type I, fibronectin, alpha-smooth muscle actin, Tamm-horsfall protein, aquaporin 1 and 2 as well as quantitative real-time PCR (qRT-PCR) for CX(3)C-L, CX(3)C-R and fibroblast-specific protein 1 (FSP-1) were performed. Additionally, regulatory mechanisms and functional activity of CX(3)C-L in murine proximal and distal tubular epithelial cells as well as in fibroblasts were investigated.
Results: CX(3)C-L/GAPDH ratio was upregulated in FAN 3.4-fold at day 7 further increasing up to 7.1-fold at day 106. The expression of mRNA CX(3)C-L correlated well with CX(3)C-R (R(2) = 0.96), the number of infiltrating CD3+ cells (R(2) = 0.60) and the degree of tubulointerstitial fibrosis (R(2) = 0.56) and moderately with FSP-1 (R(2) = 0.33). Interleukin-1beta, tumour necrosis factor-alpha, transforming growth factor-beta as well as the reactive oxygen species (ROS) H(2)O(2) were identified by qRT-PCR as inductors of CX(3)C-L/fractalkine (FKN) in tubular epithelial cells. Functionally, CX(3)C-L/FKN chemoattracts peripheral blood mononuclear cells, activates several aspects of fibrogenesis and induces the mitogen-activated protein kinases in renal fibroblasts.
Conclusions: In FAN, there is a good correlation between the expression of CX(3)C-L with markers of interstitial inflammation and fibrosis which may result from upregulation by pro-inflammatory and pro-fibrotic cytokines as well as by ROS in tubular epithelial cells. The FKN system may promote renal inflammation and renal fibrogenesis.
Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase.
Abdel-Bakky M, Aldakhili A, Ali H, Babiker A, Alhowail A, Mohammed S Pharmaceuticals (Basel). 2023; 16(7).
PMID: 37513824 PMC: 10383028. DOI: 10.3390/ph16070910.
Charlton J, Li T, Wu T, deRonde K, Xu Y, Baldelomar E BMC Nephrol. 2023; 24(1):178.
PMID: 37331957 PMC: 10278294. DOI: 10.1186/s12882-023-03196-0.
Zheng C, Xuan W, Chen Z, Zhang R, Huang X, Zhu Y Front Pharmacol. 2022; 13:848310.
PMID: 35370759 PMC: 8971671. DOI: 10.3389/fphar.2022.848310.
A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4.
Cao Q, Huang C, Yi H, Gill A, Chou A, Foley M JCI Insight. 2022; 7(4).
PMID: 35015734 PMC: 8876455. DOI: 10.1172/jci.insight.143018.
Hedayati-Moghadam M, Hosseinian S, Paseban M, Shabgah A, Gholizadeh J, Jamialahmadi T Adv Exp Med Biol. 2022; 1328:155-170.
PMID: 34981477 DOI: 10.1007/978-3-030-73234-9_11.